CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Santarus, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Santarus, Inc.
3611 Valley Centre Drive
Suite 400
Phone: (858) 314-5700p:858 314-5700 San Diego, CA  92130-3331  United States Ticker: SNTSSNTS
This company was Merged or Acquired on 4/1/2015.
This company ceased filing statements with the SEC on 1/13/2014.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company’s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company’s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201312/31/2012YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board David F.Hale 2/1/2004 6/1/2000
President, Chief Executive Officer, Director Gerald T.Proehl 54 1/1/2002 3/1/2000
Chief Financial Officer, Senior Vice President, Treasurer, Secretary Debra P.Crawford 47 12/1/2003 11/1/2000
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Covella Pharmaceuticals, Inc.
SANTARUS INC
Santarus, Inc.
SNTS

General Information
Number of Employees: 290 (As of 12/31/2012)
Outstanding Shares: 67,128,949 (As of 10/31/2013)
Shareholders: 72
Stock Exchange: NASD
Federal Tax Id: 330734433
Fax Number: (858) 314-5701


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023